Washington Draws a Line Around the Lab: The BINSA Bill and the Future of US-China Biotech Deals

For years, the flow of pharmaceutical innovation between the United States and China has been one of the defining commercial stories in global biopharma. American companies have licensed molecules from Chinese biotechs at a pace that would have seemed implausible a decade ago, and Chinese firms have gained access to US capital, clinical expertise, and regulatory know-how in return. Now, a bipartisan group of US senators wants to put that relationship under a federal microscope.

On August 7, 2026, Senators Pete Ricketts (R-NE) and Elissa Slotkin (D-MI) introduced the Biotech Investment National Security Act, known as BINSA. The bill would amend the Comprehensive Outbound Investment National Security Act, or COINS Act, to add biotechnology, including pharmaceutical development, biologics manufacturing, and clinical research, to the list of sectors subject to outbound investment screening by the US Treasury Department. In practical terms, that means licensing deals, joint ventures, and equity investments between American pharma companies and Chinese entities would face mandatory government review before they could proceed.

The Senate bill mirrors legislation introduced in the House in June 2026 by Representatives John Moolenaar and Debbie Dingell, both from Michigan. The bipartisan, bicameral momentum behind BINSA signals that this is no longer a fringe concern. It is becoming mainstream Washington policy.

The Scale of What Is at Stake

The numbers embedded in the House bill's text are striking. Cross-border out-licensing transactions between US and European pharmaceutical companies and Chinese biotech firms totaled approximately $136 billion in 2025 alone. That figure represents not just capital flows but the transfer of intellectual property, clinical data, and scientific know-how to entities that, under Chinese law, are subject to direction and control by the Chinese government. For lawmakers, that is not a commercial arrangement. It is a national security exposure.

The bill's sponsors have pointed to specific deals as evidence of the risk. Bristol Myers Squibb's $15.2 billion co-development agreement with Hengrui Pharmaceuticals, which involved sharing IP and scientific know-how, was cited as an example of the kind of transaction that would fall under BINSA's review requirements. Pfizer, AstraZeneca, and others have also struck major licensing arrangements with Chinese biotechs in recent years, deals that have been commercially attractive but that critics argue have accelerated China's pharmaceutical capabilities at America's expense.

Why the Industry Is Watching Carefully

The biopharma industry's response to BINSA has been cautious but attentive. On one hand, the deals that BINSA targets have been enormously productive for American patients. Drugs licensed from Chinese biotechs have moved through US clinical trials and reached approval, delivering new treatment options in oncology, immunology, and metabolic disease. Blocking or slowing that pipeline carries real costs for patients and for the companies that have built strategies around accessing Chinese innovation.

On the other hand, the industry has watched the BIOSECURE Act and related legislation reshape the contract research and manufacturing landscape, and it understands that Washington's appetite for scrutinizing China-linked biopharma activity is not diminishing. The question is no longer whether regulation is coming but what form it will take and how quickly it will arrive.

RA Capital Management, one of the most influential voices in biotech investing, has published analysis arguing that a sweeping ban on US-China biotech collaboration would ultimately weaken American pharmaceutical competitiveness rather than strengthen it. The argument is that China's scientific output has become genuinely world-class in certain areas, and cutting off access to that output would leave US companies and patients worse off. That perspective has found some sympathy in industry circles, but it has not slowed the legislative momentum.

A Structural Shift, Not Just a Political Moment

What makes BINSA significant beyond its immediate provisions is what it represents about the direction of US industrial policy. The bill is not simply a reaction to a single deal or a single company. It reflects a broader conviction, shared across party lines, that the United States cannot treat biotechnology as a purely commercial sector when a strategic competitor is using state resources to dominate it.

The legislation builds on the BIOSECURE Act, which targeted specific Chinese contract research organizations, and on appropriations language that would bar the FDA from accepting Chinese clinical trial data to support US drug applications. Taken together, these measures sketch the outline of a regulatory wall around the US biopharma ecosystem, one that would make it significantly harder for Chinese entities to participate in American drug development, whether as partners, suppliers, or data providers.

For companies that have built pipelines around Chinese-licensed assets, the message from Washington is becoming harder to ignore. The era of frictionless US-China biotech dealmaking may be drawing to a close, and the industry will need to decide how to adapt before the rules change around it.

BINSA has not yet passed. It faces the same legislative obstacles that have slowed similar bills in previous sessions. But the fact that it now has bipartisan Senate sponsorship, a House companion bill, and growing appropriations support suggests that the political conditions for passage are more favorable than they have ever been. The lab, it seems, is no longer just a scientific space. It is a geopolitical one.